Leerink Partnrs Has Pessimistic Outlook of ALGN Q2 Earnings

Align Technology, Inc. (NASDAQ:ALGN) – Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Align Technology in a research note issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the medical equipment provider will earn $1.90 per share for the quarter, down from their prior forecast of $2.09. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.17 EPS, FY2025 earnings at $7.46 EPS, FY2026 earnings at $8.75 EPS and FY2027 earnings at $10.20 EPS.

A number of other analysts also recently commented on ALGN. Evercore ISI boosted their target price on shares of Align Technology from $240.00 to $260.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Morgan Stanley dropped their price target on Align Technology from $280.00 to $272.00 and set an “overweight” rating on the stock in a report on Thursday, February 6th. Wells Fargo & Company started coverage on Align Technology in a research note on Friday, February 14th. They set an “overweight” rating and a $255.00 price objective for the company. Jefferies Financial Group decreased their target price on Align Technology from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Align Technology currently has an average rating of “Moderate Buy” and a consensus target price of $262.64.

Align Technology Stock Up 0.9 %

NASDAQ:ALGN opened at $165.62 on Monday. The business’s 50-day moving average price is $176.25 and its 200 day moving average price is $206.43. Align Technology has a 52-week low of $141.74 and a 52-week high of $327.49. The firm has a market cap of $12.13 billion, a P/E ratio of 29.52, a PEG ratio of 2.24 and a beta of 1.73.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 EPS for the quarter, missing analysts’ consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ALGN. Picton Mahoney Asset Management grew its stake in shares of Align Technology by 69.9% in the 4th quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in Align Technology in the fourth quarter valued at approximately $31,000. Aster Capital Management DIFC Ltd bought a new stake in Align Technology in the fourth quarter worth approximately $35,000. Private Trust Co. NA increased its stake in shares of Align Technology by 113.4% during the 4th quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 93 shares during the last quarter. Finally, Orion Capital Management LLC bought a new position in shares of Align Technology during the 4th quarter valued at $42,000. 88.43% of the stock is owned by institutional investors and hedge funds.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.